LGNZZ.US Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt

- USD
Market cap
-
P/E
-
P/B
-
ROE
0.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LGNZZ.US undervalued?

Graham number

The Graham number of Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt fundamental analysis

No fundamental analysis for Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt yet.

Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ligand Pharmaceuticals Inc Tr Beta Contingent Value Rt

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma…

Full company profile